SpringerLink
Log in

Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia

  • Original Article
  • Published:
Tumor Biology

Abstract

SET and MYND domain containing 2 (SMYD2) and the SET and MYND domain containing 3 (SMYD3) are the most studied and well-characterized members of SMYD family. It has been demonstrated that their altered expression is associated with the progression of several solid tumors. Nevertheless, whether these methyltransferases exert any impact in chronic lymphocytic leukemia (CLL) remains unknown. Here, we investigated the gene expression profile of SMYD2 and SMYD3 in 59 samples of CLL and 10 normal B cells. The obtained results were associated with white blood cells (WBC) and platelet counts, ZAP-70 protein expression, and cytogenetic analysis. We found that SMYD2 and SMYD3 are overexpressed in CLL patients and, interestingly, patients with residual expression of both genes presented a high WBC count and complex karyotype. Furthermore, a strong correlation between SMYD2 and SMYD3 gene expression was unveiled. Our data demonstrate the association of a residual expression of SMYD2 and SMYD3 with CLL progression indicators and suggests both genes are regulated by a common transcriptional control in this type of cancer. These results may provide the basis for the development of new therapeutic strategies to prevent CLL progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer. 2010;10:37–50. [Internet] Available from: http://dx.doi.org/10.1038/nrc2764.

    CAS  PubMed  Google Scholar 

  2. Gribben JG. How I, treat CLL up front. Blood. 2010;115:187–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Wiestner A. Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood. 2012;120:4684–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood. 2009;114:3367–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. De Paula Careta F, Gobessi S, Panepucci RA, Bojnik E, de Morato Oliveira F, Mazza Matos D, et al. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. Haematologica. 2012;97:1246–54. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3409824&tool=pmcentrez&rendertype=abstract.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Moreno C, Montserrat E. New prognostic markers in chronic lymphocytic leukemia. Blood Rev. 2008;22:211–9. [Internet] Available from: http://www.sciencedirect.com/science/article/pii/S0268960X08000210.

    Article  CAS  PubMed  Google Scholar 

  7. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.

    Article  CAS  PubMed  Google Scholar 

  8. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–34. [Internet] Available from: http://www.bloodjournal.org/content/46/2/219.abstract.

    CAS  PubMed  Google Scholar 

  9. Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev. 2009;23:25–47.

    Article  PubMed  Google Scholar 

  10. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control. 2012;19:18–25. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/22143059.

    PubMed  Google Scholar 

  11. Rosenquist R, Cortese D, Bhoi S, Mansouri L, Gunnarsson R. Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand? Leuk Lymphoma. 2013;54:2351–64. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23480493.

    Article  CAS  PubMed  Google Scholar 

  12. Foà R, Del Giudice I, Guarini A, Rossi D, Gaidano G. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013;98:675–85.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Gunnarsson R, Mansouri L, Rosenquist R. Exploring the genetic landscape in chronic lymphocytic leukemia using high-resolution technologies. Leuk Lymphoma. 2013;54:1583–90. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/23167608.

    Article  CAS  PubMed  Google Scholar 

  14. Kudithipudi S, Jeltsch A. Role of somatic cancer mutations in human protein lysine methyltransferases. Biochim Biophys Acta. 2014;1846:366–79. [Internet] Available from: http://www.sciencedirect.com/science/article/pii/S0304419X14000754\n http://www.ncbi.nlm.nih.gov/pubmed/25123655.

    CAS  PubMed  Google Scholar 

  15. Lund K, Adams PD, Copland M. EZH2 in normal and malignant hematopoiesis. Leukemia. 2014;28:44–9. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24097338.

    Article  CAS  PubMed  Google Scholar 

  16. Liu L, Kimball S, Liu H, Holowatyj A, Yang Z-Q. Genetic alterations of histone lysine methyltransferases and their significance in breast cancer. Oncotarget. 2015;6:2466–82.

    Article  PubMed  Google Scholar 

  17. Rabello DDA, Lucena-Araujo AR, Alves-Silva JCR, da Eira VBAS, de Vasconcellos MCC, de Oliveira FM, et al. Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. Blood Cells Mol Dis. 2014;54:97–102. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25131810.

    Article  Google Scholar 

  18. Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23:677–92. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3681809&tool=pmcentrez&rendertype=abstract.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol. 2001;112:950–8. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/11298590.

    Article  CAS  PubMed  Google Scholar 

  20. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42:181–5. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2850970&tool=pmcentrez&rendertype=abstract.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Lim Choi Y, et al. Overexpression of enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy. Haematologica. 2011;96:712–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sakamoto LHT, De Andrade RV, Felipe MSS, Motoyama AB, Pittella Silva F. SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor. Leuk Res. 2014;38:496–502. [Internet]. Available from: http://dx.doi.org/10.1016/j.leukres.2014.01.013.

    Article  CAS  PubMed  Google Scholar 

  23. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, et al. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004;6:731–40.

    Article  CAS  PubMed  Google Scholar 

  24. Trievel RC, Beach BM, Dirk LMA, Houtz RL, Hurley JH. Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell. 2002;111:91–103.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang X, Tamaru H, Khan SI, Horton JR, Keefe LJ, Selker EU, et al. Structure of the Neurospora SET domain protein DIM-5, a histone H3 lysine methyltransferase. Cell. 2002;111:117–27. [Internet] Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2713760&tool=pmcentrez&rendertype=abstract.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Veraksa A, Kennison J, McGinnis W. DEAF-1 function is essential for the early embryonic development of Drosophila. Genesis. 2002;33:67–76. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/12112874.

    Article  CAS  PubMed  Google Scholar 

  27. Silva FP, Hamamoto R, Kunizaki M, Tsuge M, Nakamura Y, Furukawa Y. Enhanced methyltransferase activity of SMYD3 by the cleavage of its N-terminal region in human cancer cells. Oncogene. 2008;27:2686–92. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17998933.

    Article  CAS  PubMed  Google Scholar 

  28. Komatsu S, Ichikawa D, Hirajima S, Nagata H, Nishimura Y, Kawaguchi T, et al. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer. Br J Cancer. 2015;112:357–64. [Internet] Available from: http://dx.doi.org/10.1038/bjc.2014.543.

    Article  CAS  PubMed  Google Scholar 

  29. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura Y, et al. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113–8. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16441421.

    Article  CAS  PubMed  Google Scholar 

  30. Hu L, Zhu YT, Qi C, Zhu Y-J. Identification of Smyd4 as a potential tumor suppressor gene involved in breast cancer development. Cancer Res. 2009;69:4067–72. [Internet]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19383909.

    Article  CAS  PubMed  Google Scholar 

  31. Matutes E, Owusu-Ankomah K, Morilla R, Garcia Marco J, Houlihan A, Que TH, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 1994;8:1640–5.

    CAS  Google Scholar 

  32. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29, e45. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/11328886.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987;60:2712–6.

    Article  CAS  PubMed  Google Scholar 

  34. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–56. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/18216293.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5:691–701.

    Article  CAS  PubMed  Google Scholar 

  36. Gandhirajan RK, Poll-Wolbeck SJ, Gehrke I, Kreuzer K. Wnt/β-catenin/LEF-1 signaling in chronic lymphocytic leukemia (CLL): a target for current and potential therapeutic options. Curr Cancer Drug Targets. 2010;10:716–27. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20578984.

    Article  CAS  PubMed  Google Scholar 

  37. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6.

    Article  PubMed  Google Scholar 

  38. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood. 2006;107:742–51. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16179374.

    Article  CAS  PubMed  Google Scholar 

  39. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006;444:629–32. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17108971.

    Article  CAS  PubMed  Google Scholar 

  40. Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol. 2010;188:369–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Fujiwara T, Bandi M, Nitta M, Ivanova EV, Bronson RT, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature. 2005;437:1043–7.

    Article  CAS  PubMed  Google Scholar 

  42. Dicker F, Herholz H, Schnittger S, Nakao A, Patten N, Wu L, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leuk Off J Leuk Soc Am Leuk Res Fund, UK. 2009;23:117–24.

    Article  CAS  Google Scholar 

  43. Cho HS, Hayami S, Toyokawa G, Maejima K, Yamane Y, Suzuki T, et al. RB1 methylation by SMYD2 enhances cell cycle progression through an increase of RB1 phosphorylation. Neoplasia. 2012;14:476–86. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394190/pdf/neo1406_0476.pdf.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Saddic LA, West LE, Aslanian A, Yates JR, Rubin SM, Gozani O, et al. Methylation of the retinoblastoma tumor suppressor by SMYD2. J Biol Chem. 2010;285:37733–40. [Internet] Available from: http://www.jbc.org/content/285/48/37733.long.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25:1628–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Mazur PK, Reynoird N, Khatri P, Jansen PWTC, Wilkinson AW, Liu S, et al. SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer. Nature. 2014;510:283–7. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/24847881.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761–74. [Internet] Available from: http://dx.doi.org/10.1038/nrc3106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Yang G, Mercado-Uribe I, Multani AS, Sen S, Shih IM, Wong KK, et al. RAS promotes tumorigenesis through genomic instability induced by imbalanced expression of Aurora-A and BRCA2 in midbody during cytokinesis. Int J Cancer. 2013;133:275–85.

    Article  CAS  PubMed  Google Scholar 

  49. Lucena-Araujo AR, de Oliveira FM, Leite-Cueva SD, dos Santos GA, Falcao RP, Rego EM. High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia. Leuk Res. 2011;35:260–4. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/20732714.

    Article  CAS  PubMed  Google Scholar 

  50. Tsuge M, Hamamoto R, Silva FP, Ohnishi Y, Chayama K, Kamatani N, et al. A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5’ flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005;37:1104–7. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/16155568.

    Article  CAS  PubMed  Google Scholar 

  51. Coschi CH, Dick FA. Chromosome instability and deregulated proliferation: an unavoidable duo. Cell Mol Life Sci. 2012;69:2009–24.

    Article  CAS  PubMed  Google Scholar 

  52. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-B activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563–74. [Internet] Available from: http://www.bloodjournal.org/content/117/2/563.abstract.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Tavolaro S, Colombo T, Chiaretti S, Peragine N, Fulci V, Ricciardi MR, et al. Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. Genes Chromosomes Cancer. 2015;54:222–34. [Internet] Available from: http://www.ncbi.nlm.nih.gov/pubmed/25645730.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The present study was funded by CNPq (National Council of Technological and Scientific Development), CAPES (Coordination for the Improvement of Higher Education Personnel), and FAPDF (Federal District Research Foundation).

Authors’ contribution

WOS and DAR were both responsible for conception and design, collection and/or assembly of data, data analysis and interpretation, and manuscript writing. ARLA was both responsible for conception and design, provision of study material or patients, collection and/or assembly of data, and manuscript writing. FMO was both responsible for conception and design, provision of study material or patients, and collection and/or assembly of data. EMR was both responsible for provision of study material or patients and collection and/or assembly of data. FPS was both responsible for conception and design, provision of study material or patients, data analysis, and manuscript writing. FSA was both responsible for conception and design, provision of study material or patients, data analysis, and manuscript writing. All authors read and approved the final manuscript.

Author information

Authors and Affiliations

  1. Laboratory of Molecular Pathology of Cancer, Faculty of Health Sciences, University of Brasília, Av. L2 Norte, Brasília, DF, 70.910-900, Brazil

    Wilson Oliveira-Santos, Doralina Amaral Rabello, Fábio Pittella Silva & Felipe Saldanha-Araujo

  2. Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Av. Bandeirantes 3900, Ribeirão Preto, SP, 14.048-900, Brazil

    Antônio Roberto Lucena-Araujo, Fábio Morato de Oliveira & Eduardo Magalhaes Rego

Authors
  1. Wilson Oliveira-Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doralina Amaral Rabello
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antônio Roberto Lucena-Araujo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fábio Morato de Oliveira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eduardo Magalhaes Rego
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Fábio Pittella Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Felipe Saldanha-Araujo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Felipe Saldanha-Araujo.

Ethics declarations

Conflicts of interest

None

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oliveira-Santos, W., Rabello, D.A., Lucena-Araujo, A.R. et al. Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia. Tumor Biol. 37, 9473–9481 (2016). https://doi.org/10.1007/s13277-016-4846-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4846-z

Keywords

Search

Navigation